|M9444||Cenicriviroc Mesylate||Cenicriviroc Mesylate is a dual CCR2/CCR5 antagonist, and it also inhibits both HIV-1 and HIV-2.|
|M9135||TAK-779||TAK-779 is a potent and selective nonpeptide antagonist of CCR5, with a Ki of 1.1 nM for CCR5.|
|M9131||ZK-756326 dihydrochloride||ZK-756326 dihydrochloride is a potent, selective and non-peptide CCR8 chemokine receptor agonist.|
|M9006||NSC5844||NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.|
|M8986||CCX140||CCX140 is a potent CCR2 antagonist.|
|M8254||SB 297006||SB 297006 is an antagonist of CCR3 with IC50 of 39 nM.|
|M7224||RS 504393||RS 504393 is a highly selective CCR2 chemokine receptor antagonist.|
|M6263||INCB3284 dimesylate||INCB 3284 dimesylate is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM.|
|M6249||BMS-813160||BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.|
|M2032||Vicriviroc Malate||Vicriviroc (SCH 417690) is a pyrimidine CCR5 entry inhibitor of HIV-1 with IC50 of 0.91 nM.|
|M1971||Maraviroc||Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.